News – Page 998 – Endpoints News

Hong Kong IPO delivers $421M to Innovent as another one of China's biotech unicorns hauls in big money

7 years ago

Alexion doles out $22M upfront for two preclinical RNAi drugs from Dicerna

7 years ago

Nav1.7 analgesic failures stack up as Biogen abandons vixotrigine after latest setback

7 years ago

Amid repeated stumbles, Pfizer and Eli Lilly tout their anti-NGF pain drug tanezumab — but questions linger

7 years ago

NeoGenomics spends $125M to expand ops; Cara hires Celgene exec as CMO

7 years ago

Antisense startup Stoke Therapeutics secures another $90M in series B funding

7 years ago

Bain’s Adam Koppel commits $350M to launching a new biotech that is carving out Pfizer’s neuro pipeline

7 years ago

UCB, Biogen admit defeat in PhII lupus trial, adding to a string of late-stage failures in the field

7 years ago

Enterome fortifies Takeda relationship with $50M upfront to co-develop Crohn's drug

7 years ago

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus

7 years ago

Rattled by setbacks, Celgene turns to ex-Merck R&D star Alise Reicin to repair its damaged development rep

7 years ago

In key endorsement, Deerfield reserves $65M for drug venture with UNC-Chapel Hill

7 years ago

Medicines Co execs grab a $33M A round to spin out an infectious disease outfit with a pipeline

7 years ago

Dupixent wins FDA OK for asthma; Seres poaches new CMO from AstraZeneca

7 years ago

#ESMO18: Novartis claims a key win in breast cancer with PI3K drug alpelisib

7 years ago

Fidelity, Valor pool $71.8M for Jeff Aronin's plan to reformulate a generic for butterfly skin disease at Castle ...

7 years ago

Winners and losers at #ESMO18

7 years ago

One of Hal Barron's top drug prospects at GSK flunks a PhII test for rheumatoid arthritis, flailing in an intensely ...

7 years ago

Chipping away at Gilead's HIV empire, GSK's ViiV submits NDA for 2-drug HIV regimen -- playing voucher card for ...

7 years ago

TP Therapeutics grabs $80M mezzanine round to fund a pivotal trial for ROS-1/NTRK-positive cancers

7 years ago

#ESMO18: Cardio dreams blighted, Novartis showcases its “blockbuster” ambitions for radiopharmaceuticals

7 years ago

Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop

7 years ago

#ESMO18: Crowned with a breakthrough title, Clovis takes an early lead as it races for a fast OK for Rubraca in ...

7 years ago

Merck previews an early hit with Keytruda combo for kidney cancer, putting more pressure on rival Bristol-Myers

7 years ago

First page Previous page 995 996 997998999 1000 1001 Next page Last page